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Circulating immune complexes in cutaneous and systemic vascu-
litis. J. Barratt, M. Sindrey, and P. Naish. Medical Research
Laboratories, North Staffordshire Medical Centre, Stoke-on-
Trent, Staffordshire, England. Studies of circulating immune
complexes in patients with vasculitis were carried out by using a
radiolabeled monoclonal rheumatoid factor binding (RFB) assay.
A very high proportion of patients showed high RFB in the acute
phase of the disease. Eight patients with systemic vasculitis were
studied serially, and RFB correlated well with clinical and other
laboratory evidence of disease activity in all but one patient.
Sepharose 6B gel filtration studies of high RFB sera showed that
complexes are small (3 to 4 x l0 daltons) regardless of serum
complement levels or the extent of the disease. Fractions eluted
from the Sepharose 613 column were further analyzed by binding
to, and subsequent acid elution from, a protein A-Sepharose col-
umn, which binds IgG-containing molecules. Analysis of the
eluted material failed to show immunoglobulins other than IgG or
complement components in the I x 106 to 3 x l0 dalton range,
but 1gM and IgG were detected in the >1 x 106 dalton range in
one of the four samples tested so far, again without complement
components. These findings were discussed in relation to the
clinical management of vasculitis, and the possible relationship
between circulating and tissue bound complexes.
Significance of circulating immune complexes in idiopathic gb-
merulonephritis. S. A. Cairns, R. A. London, and N. P. Mallick.
Manchester Royal Infirmary, Manchester, England. We have
used three approaches in studying the role of immune complexes
in glomerulonephritis (GN). First, circulating immune complexes
(IC) were measured in 265 serum samples from 130 patients with
established biopsy-proven minimal change, membranous, and
diffuse proliferative GN by using three techniques chosen to de-



































% Positive in at least
one assay 61.1 65.8 63.2
In all histologic categories, a variety of IC was detected. IgG
containing non-Clq binding complexes predominated in minimal
change GN. Neither in minimal change nor in the other two
groups could levels of complexes be correlated with the degree
of proteinuria, declining renal function, or duration of relapse.
Second, the size of the complexes present was analyzed by
Sepharose 6B gel column chromatography. A wide range of com-
plex sizes was found in sera from each histologic group, but no
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particular size predominated and there was no evidence of the
excess of middle range complexes (900,000 daltons) that we
found in lupus nephritis. Third, we have demonstrated that pa-
tients with GN show impaired handling of the IC that circulate
during the normal metabolism of ingested macromolecules. This
finding offers an explanation for the poor correlation between IC
levels and disease activity, The majority of complexes detected
in a random sample may be merely markers of an underlying
immune defect, and present techniques do not permit separate
identification of pathogenic complexes in idiopathic GN.
Tamm-Horsfall glycoprotein in serum. A. B. St. J. Dawnay and
W. R. Cattell. Department of Nephrology, St. Bartholomew's
Hospital, London, England. Since it was first demonstrated in
1950. Tamm-Horsfall glycoprotein (THG) has been considered a
renal-specific glycoprotein found only in urine. However, ad-
vances in knowledge of the clinical significance of this glycopro-
tein have been hampered by considerable difficulties in devel-
oping quick and accurate assay methods. It has been claimed
that THG is not normally present in the circulation and further
postulated that only with renal damage can the glycoprotein en-
ter the interstitium of the kidney and hence the blood. Being
"foreign" to the circulation, its presence in the blood would in-
duce antibody production. Fundamental to this hypothesis is
whether or not THG is normally present in the circulation. We
developed a sensitive and specific radioimmunoassay technique
capable of detecting THG in serum. Using this technique we
have clearly demonstrated the presence of THG in the serum of
normal subjects and, by means of this assay and chromatograph-
ic studies, that it is mainly present in a nonaggregated form with
a mol wt of 73,000 daltons. Serum levels are significantly reduced
in patients with severe chronic renal disease and fall markedly
following uninephrectomy in kidney transplant donors. No THU
could be detected in the serum of anephnc subjects maintained
on hemodialysis. Our findings confirm that THG is a renal-specif-
ic glycoprotein and also show that it is present in the serum of
normal subjects. The factors determining the serum level of THG
remain to be fully defined, but preliminary results suggest that
measurement of these levels may prove a valuable marker of ren-
al disease.
Adaptive changes in the piscine glomerulus to variation in salini-
ty. J. W. Dobbie and R. Richards. Tenovus Kidney Diseases Re-
search Unit, Royal Infirmary. Glasgow, Scotland. The basic
structure of piscine and mammalian glomeruli is identical. More-
over, presumed evolution from a common ancestor suggests that
the vertebrate glomerulus has existed for a considerable period
of geological time. Its persistence in animals of divergent form,
living in different environments, implies a remarkable degree of
flexible utility. Thus, the study of naturally occurring alterations
of the piscine glomerulus in response to varying salinity may be
relevant to a postulated innate adaptive potential of the verte-
brate glomerulus. A morphologic and morphometric assessment
of glomerular changes, made in 60 salmon, before and after vary-
ing periods of exposure to sea water (30 mm to 18 months),
s'owed that after 1 month in sea water there was a reduction in
5ize and vasculanty of the glomerular tuft but that the urinary
space was diminished by a proliferation of epithelial cells. These
changes could explain the marked fall in urine output known to
occur when salmonids move from fresh to salt water and may be





analogous to the prolactin-responsive glomerular changes de-
scribed in the migrating stickleback. These naturally occurring
alterations in glomerular structure are mimicked by changes en-
countered in human glomerulopathies.
Serum immunoglobulins in glomerulonephritis. H. Rashid, G.
Drivas,A. W. Skillen, A. R. Morley, and D. N. S. Kerr. Depart-
ments of Medicine, Pathology and Clinical Biochemistry, Uni-
versity of Newcastle upon Tyne, England. Serum immunoglobu-
lin concentrations were measured in 176 patients with various
types of glomerulonephritis and were correlated with serum pro-
tein, serum albumin, and proteinuria. Serum IgG was decreased
in all types of glomerulonephritis (P < 0.01 to <0.0001) except
Berger's nephritis. Serum IgA was reduced only in minimal
change (P < 0.001) and membranoproliferative glomerulonephri-
tis (P < 0.03). On the other hand, serum 1gM was not decreased
in any group and was significantly raised (P < 0.002) in minimal
change glomerulonephritis. The decreased serum levels of IgG
and IgA in minimal change and membranoproliferative nephritis
cannot be accounted for entirely by urinary losses. Six patients
with minimal change glomerulonephntis responded to treatment
with prednisone; serum IgG rose (P < 0.005) and serum 1gM fell(P < 0.05), but concentrations were not always restored to nor-
mal. The possibility that minimal change glomerulonephritis is
associated with an abnormality of T-cell function, as suggested
by several authors, was discussed in the light of these findings.
Twelve patients with proliferative glomerulonephritis received
cyclophosphamide, which did not result in remission. There was
no significant change in serum IgG, but the fall in serum 1gM was
significant (P < 0.005).
Alterations in red cell carrier-mediated cation transport in Bar-
tter's syndrome: A possible cause of the disease. L. R. Solomon,
H. Bobinski, and N. P. Mallick. Renal Unit, Manchester Royal
Infirmary, and Department of Physiology, University of Man-
chester, England. Red cell membranes are believed to transport
sodium and potassium in at least four ways: (1) The Na-K pump
(ATPase), which can be inhibited by ouabain (pump 1); (2) Car-
rier-mediated and frusemide-sensitive outward transport of so-
dium (pump 11); (3) Carrier-mediated inward cotransport of so-
dium and potassium, which can be inhibited by frusemide or
removal of one of the two ions from the incubation medium; (4)
Passive diffusion. We have studied all measurable variables of
red cell sodium transport in 13 hypokalemic patients, 8 of whom
had Bartter's syndrome and 5 of whom were hypokalemic for
other reasons. Bartter's syndrome was diagnosed on the basis of
hypokalemia, renal potassium wasting, normal or alkalotic acid-
base state, hyperreninemia, and a normal or low blood pressure.
All patients with Bartter's syndrome showe.d altered carrier-me-
diated sodium influx (system 3 above), and there seemed to be
two variants of this abnormality. In type 1, the magnitude of the
frusemide-sensitive component was increased, although the per-
cent inhibition following the removal of potassium was de-
creased. In type 2, the magnitude of the frusemide-sensitive
component of sodium influx was normal, although the percent
inhibition following potassium removal was also decreased.
These alterations were unaffected by treatment of the patients
with prostaglandin synthetase inhibitors and were not found in
the 5 patients hypokalemic for other reasons or in 2 patients re-
quiring large doses of frusemide for the nephrotic syndrome.
Two of the type 2 patients had normokalemic children, who also
had the transport defect. In these patients, Bartter's syndrome is
associated with an inherited abnormality of the protein involved
in carrier-mediated, frusemide-sensitive, cotransport of sodium
and potassium, which results in a decreased affinity of the carrier
for potassium.
Enzyme-linked immunosorbent assay (ELISA) for measurement
of circulating antiglomerular basement membrane antibodies. J.
Wheeler and M. Sussman. Department of Microbiology, Univer-
sit)' of Newcastle upon Tyne, England. A sensitive and reproduc-
ible enzyme-linked immunosorbent assay (ELISA) has been de-
vised for the measurement of circulating antibodies to glomerular
basement membrane (GBM). The immunoadsorbent is a collage-
nase digest of GBM, prepared by a modification of the method of
Spiro, adsorbed onto the internal surface of polystyrene tubes.
The assay is carried out in the immunoadsorbent tubes by the
sequential incubation of the test serum, antihuman lgG-alkaline
phosphatase conjugate, and, finally, para-nitrophenylphosphate.
After standard incubation with substrate, the reaction is termi-
nated by addition of alkali, and the absorbances are determined
spectrophotometrically at 400 nm. The absorbance is directly
proportional to the amount of anti-GBM antibody bound from
the test serum. The assay is quantitated in terms of arbitrary anti-
body units (a.a.u.) by relating the absorbances given by test sera
to a standard curve obtained with a serum from a patient with
known anti-GBM nephritis. With this technique, we have exam-
ined sera from normal controls, from patients with various forms
of renal disease, and from patients with elevated ASO titres (>
333 Canadian units/ml). In 9 patients with the clinical and histo-
logic features of anti-GBM nephritis, 19 out of 31 sera contained
between 18 and 200 a.a.u. of activity. The remaining 12 sera from
these patients contained less than 10 a.a.u. and were taken either
during remission or after nephrectomy. Sera from 40 patients
with other types of renal disease, including chronic glomerulone-
phritis, proliferative glomerulonephritis, anaphylactoid purpura,
systemic lupus erythematosus, membranous glomerulonephritis,
membranoproliferative glomerulonephritis, chronic proliferative
glomerulonephritis, rapidly progressive glomerulonephntis,
polyarteritis nodosa, and amyloidosis, gave values of less than 7
a.a.u., as did sera from 6 patients with elevated ASO titres. Con-
trol normal human sera also consistently gave values of less than
7 a.a.u. The design and standardization of the assay were de-
scribed, and its application in the management of patients with
anti-GBM nephritis were discussed.
Activity-concentration curves for inhibitors and promoters of
calcium oxalate crystal growth. E. J. Will, J. Bevan, and 0. L. M.
Bijvoet. Renal Unit, Nottingham City Hospital, Department of
Medicine, Nottingham University, and Department of Clinical
Endocrinology, University Hospital, Leiden, The Netherlands.
Crystalline calcium oxalate is the commonest constituent of ren-
al calculi. Crystallisation must occur at a rate dependent on (1)
urinary supersaturation, (2) the density of heterogenous nuclei or
preformed crystal/stone surface, and (3) the concentration of in-
hibitory or promoting substances. It is impossible to measure the
last in whole urine with physiologic crystal surface densities and
at known supersaturations. A compromise is necessary for one
or other variable. We have used a diluted system of standardized
supersaturation to measure crystal growth, and can readily pro-
duce curves relating inhibitory activity to the concentration of a
number of inhibitors, including urine. These measurements were
independent of crystal surface density. Pyrophosphate and urine
gave similar curves when measured after 20 mm of crystal
growth, with ever-increasing slopes of inhibitory activity accord-
ing to rising concentration. The pyrophosphate curve was linear,
however, when measured at 60 mm. This was consistent with
classical adsorption theory, and indicated an "induction period"
which complicated early readings. Heparin, by contrast, gave
sigmoid curves, with a plateau of inhibitory potency despite a 50-
fold rise in concentration in the middle of the effective range.
This was independent of incubation time after 10 mm, but at ear-
lier intervals there was greater crystal growth than was expected
from later measurements of inhibition. Other polymeric sulpho-
nates and amino acids gave similar curves. The variation in
shape of these curves is unexplained, but suggests different modes
of action for pyrophosphate, urine, and heparin. The sigmoid
curve of polymeric inhibitors may be important in vivo, since
inhibitory activity will decline suddenly with increase in dilution.
This could produce a "threshold" effect where urinary glyco-
saminoglycans are concerned. The early "promotion" of crystal
growth by heparin occurs within the transit time of urine through
the upper urinary tract.
